Sarepta Therapeutics (SRPT) Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SRPT shares.
View SRPT analyst ratings or view top-rated stocks.

15 brokers have issued 12-month price targets for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $125.00 to $223.00. On average, they anticipate the company's stock price to reach $173.70 in the next twelve months. This suggests a possible upside of 44.2% from the stock's current price.
View analysts price targets for SRPT or view top-rated stocks among Wall Street analysts.

Sarepta Therapeutics' stock was trading at $129.58 on January 1st, 2023. Since then, SRPT shares have decreased by 7.0% and is now trading at $120.45.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our SRPT earnings forecast.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($1.89) by $1.62. The biotechnology company earned $261.20 million during the quarter, compared to analysts' expectations of $255.99 million. Sarepta Therapeutics had a negative net margin of 90.46% and a negative trailing twelve-month return on equity of 91.22%. The company's revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the company posted ($2.65) earnings per share.

ETFs with the largest weight of Sarepta Therapeutics (NASDAQ:SRPT) stock in their portfolio include Morningstar US Small Growth (MSGR), Global X Genomics & Biotechnology ETF (GNOM), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and American Century Mid Cap Growth Impact (MID).

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRPT stock can currently be purchased for approximately $120.45.

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $10.60 billion and generates $933.01 million in revenue each year. The biotechnology company earns $-703,490,000.00 in net income (profit) each year or ($10.31) on an earnings per share basis.

The company employs 1,162 workers across the globe.

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.